deupirfenidone

Deupirfenidone is a selectively deuterated form of the antifibrotic agent pirfenidone, developed to retain the potent anti-fibrotic and anti-inflammatory activity of its parent compound while offering improved pharmacokinetics and tolerability. As an orally bioavailable small molecule, it inhibits pro-inflammatory mediators such as interleukin‑6 (IL‑6), tumor necrosis factor-alpha (TNF‑α), and transforming growth factor-beta (TGF‑β). This mechanism reduces fibrosis and inflammation, particularly in the lungs, making it a promising candidate for idiopathic pulmonary fibrosis (IPF). Deupirfenidone has demonstrated dose-dependent efficacy in slowing lung function decline in phase 2b clinical trials for IPF, with a favorable safety profile compared to standard-of-care treatments[1][2][5][8].

Other names

deuterated pirfenidonedeuterium-substituted pirfenidonepirfenidone deuterated